The Middle East and Africa Cell Expansion Market size have been calculated at USD 2.05 billion in 2022. This value is further projected to be growing at a CAGR of 14.9% and worth USD 4.10 billion by 2027.
The rising incidence of chronic diseases, government funding in cell-based research, the expanding focus on personalized medicine, increasing focus on R&D for cell-based therapeutics, and growing GMP certifications for cell therapy manufacturing facilities are driving growth in this market. In the development of drugs for the treatment of diseases, cell expansion is used. Vaccines, medicines, therapies, and antibiotics are all made with it. In addition, diseases like diabetes and cancer are becoming more common, necessitating more thorough studies to identify new treatment alternatives.
Chronic disorders like diabetes, rheumatoid arthritis, and cancer are on the rise, propelling the MEA cell expansion market forward. In addition, government agencies are releasing funding for stem cell research and other types of research, which will help the market for cell expansion systems grow. Multinational corporations are investing in the development of cell expansion systems because they reduce the danger of contamination, improve cell density, allow for controlled cell growth, and may be used in a regulated environment.
The MEA cell expansion industry has profitable opportunities due to the rise in opportunity in this region and the increased focus on personalized treatment. Cell expansion bioreactors are quick to set up and do not have to be cleaned or sterilized regularly. The advantage of employing cell expansion systems in the pharmaceutical, biotechnology, or research organizations is that they are extremely dependable and assure proper cell culture mixing and aeration. In CTP manufacturing, the paradigm change toward Single-Use Systems (SUS) offers significant productivity benefits. Cross-contamination and culture contamination caused by improper sterilization is no longer an issue with SUS. In the life sciences field, cellular therapies are continually gaining favor. The market is being driven by an increase in funding from private and government organizations and activities undertaken by them to support the development of cellular therapies. The International Society for Stem Cell Research works to identify stem cell-related funding opportunities in various biological fields.
The cell expansion market's growth in the MEA region may be hampered by ethical concerns about cell biology research, a scarcity of trained experts, and the high cost of cell-based treatments. Therefore, in the coming years, the market is expected to be constrained by a scarcity of skilled specialists and expensive initial costs. In addition, in the approaching years, a lack of high-tech instrumentation and 3D cell expansion technology is going to be a challenge.
This research report on the Middle East and Africa cell expansion market has been segmented and sub-segmented into the following categories.
By Cell Type:
The expansion of the Middle East and Africa cell expansion market is fuelled by an increase in cell therapy transplantation procedures, increased research and development efforts, and increased investments in developing production facilities for cell and gene therapy products. Furthermore, due to an increase in government financing initiatives, which has accelerated the synthesis of stem cells and the development of regenerative medicine and cellular therapy products. As a result, demand for cell expansion platforms in this region is on the rise.
KEY MARKET PLAYERS:
Some of the prominent companies leading the Middle East & Africa cell expansion market profiled in the report include Beckman Coulter, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Corning, Inc. (U.S.), GE Healthcare (U.K.), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com